Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial
M.W. Lucas, A.M. Menzies, Marta López‐Yurda, Richard A. Scolyer, B. van de Wiel, R.P.M. Saw, W. Van Houdt, Nigel Maher, A. Torres Acosta, M. Boers-Sonderen, G. Hospers, M.S. Carlino, Jan Willem de Groot, E. Kapiteijn, K. Suijkerbuijk, P. Rutkowski, Shahneen Sandhu, Astrid A.M. van der Veldt, G.V. Long, C.U. Blank (2024). LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial. , 35, DOI: https://doi.org/10.1016/j.annonc.2024.08.2283.
Article306 days agoNeoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.
Christian U. Blank, Minke W. Lucas, Richard A. Scolyer, Bart A. van de Wiel, Alexander M. Menzies, Marta López‐Yurda, Alexander Christopher Jonathan Van Akkooi, Winan J. van Houdt, Robyn P.M. Saw, Alex Torres Acosta, Serigne Lo, Geke A.P. Hospers, Matteo S. Carlino, Jan Willem de Groot, Ellen Kapiteijn, Karijn P.M. Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, Astrid Aplonia Maria Van Der Veldt, Georgina V. Long (2024). Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.. , 42(17_suppl), DOI: https://doi.org/10.1200/jco.2024.42.17_suppl.lba2.
Article306 days agoLBA57 Two-year clinical update and first biomarker analyses of the phase III NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma
M.W. Lucas, A.M. Menzies, P. Dimitriadis, S C M A Wijnen, Marta López‐Yurda, Richard A Scolyer, B. van de Wiel, Robyn P.M. Saw, A. Kuijpers, A. Torres Acosta, Joyce Sanders, M.S. Carlino, Jan Willem de Groot, E. Kapiteijn, K. Suijkerbuijk, P. Rutkowski, Shahneen Sandhu, Astrid A.M. van der Veldt, G.V. Long, C.U. Blank (2025). LBA57 Two-year clinical update and first biomarker analyses of the phase III NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma. , 36, DOI: https://doi.org/10.1016/j.annonc.2025.09.069.
Article44 days agoLong-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trial
Christian U. Blank, Lotte Hoeijmakers, Petros Dimitriadis, S C M A Wijnen, Irene L. M. Reijers, Marta López‐Yurda, Alexander M. Menzies, Annegien Broeks, Sten Cornelissen, Alex Torres Acosta, Anja van der Wal, Robyn P.M. Saw, Judith M. Versluis, Winan J. van Houdt, Michel W.J.M. Wouters, Jurriaan Romano, Elisa A. Rozeman, L. Grijpink-Ongering, Ellen Kapiteijn, Astrid van der Veldt, Karijn P.M. Suijkerbuijk, Hanna Eriksson, Geke A.P. Hospers, Jos A. van der Hage, Dirk J. Grünhagen, Arjen J. Witkamp, Judith Lijnsvelt, W. Martin C. Klop, Charlotte L. Zuur, Annemarie Bruining, Abrahim Al-Mamgani, Thomas E. Pennington, Kerwin F. Shannon, Sydney Ch’ng, Andrew J. Colebatch, Maria Gonzalez, Andrew Spillane, John B.A.G. Haanen, Robert V. Rawson, Richard A Scolyer, Bart A. van de Wiel, Alexander C.J. van Akkooi, Georgina V. Long (2025). Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trial. , DOI: https://doi.org/10.21203/rs.3.rs-7090131/v1.
Preprint44 days ago1614P Long-term outcome of adding the histone deacetylase inhibitor (HDACi) domatinostat (DOM) to neoadjuvant (neoadj) nivolumab (NIVO) +/- ipilimumab (IPI) in interferon-gamma signature (IFNγ) high/low stage III melanoma patients (pts)
Lianne Hoeijmakers, Irene L. M. Reijers, A.M. Menzies, Petros Dimitriadis, Marta López‐Yurda, Sten Cornelissen, Michel W.J.M. Wouters, R. Saw, M. Klop, Thomas E. Pennington, W. Van Houdt, L.J.W. Bosch, L. Grijpink-Ongering, R. Rawson, Andrew J. Spillane, Richard A Scolyer, B. van de Wiel, Alexander C.J. van Akkooi, G.V. Long, C.U. Blank (2025). 1614P Long-term outcome of adding the histone deacetylase inhibitor (HDACi) domatinostat (DOM) to neoadjuvant (neoadj) nivolumab (NIVO) +/- ipilimumab (IPI) in interferon-gamma signature (IFNγ) high/low stage III melanoma patients (pts). , 36, DOI: https://doi.org/10.1016/j.annonc.2025.08.2242.
Article44 days ago